Gilead and Lyndra co-develop long-acting HIV therapies 11-Jul-2019 By Vassia Barba Following Gilead’s funding of Lyndra’s technology, the latter company offers exclusive rights to its therapeutics platform for long-acting HIV therapies formulations.